Original article Pharmacokinetics, safety, and tolerability following single-dose migalastat hydrochloride (GR181413A/AT1001) in healthy male Japanese subjects

作者： Takumi Terao , Hiroko Ino , Naoki Takahashi

DOI:

关键词: Tolerability 、 Pharmacokinetics 、 Medicine 、 Pharmacology 、 Migalastat Hydrochloride

摘要:

暂无可下载资源，当前可以选择系统获取到有开放资源时通知我或者直接发起求助文献求助

参考文章(11)

R Charles Scriver, The Metabolic and Molecular Bases of Inherited Disease ,(1995)

Jian-Qiang Fan, Satoshi Ishii, Naoki Asano, Yoshiyuki Suzuki, Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nature Medicine. ,vol. 5, pp. 112- 115 ,(1999) , 10.1038/4801

Franklin K. Johnson, Paul N. Mudd, Alexander Bragat, Mathews Adera, Pol Boudes, Pharmacokinetics and Safety of Migalastat HCl and Effects on Agalsidase Activity in Healthy Volunteers Clinical pharmacology in drug development. ,vol. 2, pp. 120- 132 ,(2013) , 10.1002/CPDD.1

Christine M Eng, Dominique P Germain, Maryam Banikazemi, David G Warnock, Christoph Wanner, Robert J Hopkin, Jan Bultas, Philip Lee, Katherine Sims, Scott E Brodie, Gregory M Pastores, Joerg M Strotmann, William R Wilcox, Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genetics in Medicine. ,vol. 8, pp. 539- 548 ,(2006) , 10.1097/01.GIM.0000237866.70357.C6

Gary Hin-Fai Yam, Nils Bosshard, Christian Zuber, Beat Steinmann, Jürgen Roth, Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants American Journal of Physiology-cell Physiology. ,vol. 290, ,(2006) , 10.1152/AJPCELL.00426.2005

Jian-Qiang Fan, A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity Trends in Pharmacological Sciences. ,vol. 24, pp. 355- 360 ,(2003) , 10.1016/S0165-6147(03)00158-5

Roscoe O. Brady, Andrew E. Gal, Roy M. Bradley, Erik Martensson, Andrew L. Warshaw, Leonard Laster, Enzymatic Defect in Fabry's Disease New England Journal of Medicine. ,vol. 276, pp. 1163- 1167 ,(1967) , 10.1056/NEJM196705252762101

Gary Hin-Fai Yam, Christian Zuber, Jürgen Roth, A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder The FASEB Journal. ,vol. 19, pp. 12- 18 ,(2005) , 10.1096/FJ.04-2375COM

J. A. KINT, The enzyme defect in Fabry's disease. Nature. ,vol. 227, pp. 1173- 1173 ,(1970) , 10.1038/2271173B0

10.

E. R. Benjamin, J. J. Flanagan, A. Schilling, H. H. Chang, L. Agarwal, E. Katz, X. Wu, C. Pine, B. Wustman, R. J. Desnick, D. J. Lockhart, K. J. Valenzano, The pharmacological chaperone 1-deoxygalactonojirimycin increases α-galactosidase A levels in Fabry patient cell lines Journal of Inherited Metabolic Disease. ,vol. 32, pp. 424- 440 ,(2009) , 10.1007/S10545-009-1077-0

Original article Pharmacokinetics, safety, and tolerability following single-dose migalastat hydrochloride (GR181413A/AT1001) in healthy male Japanese subjects

来源期刊

我的账户

Original article Pharmacokinetics, safety, and tolerability following single-dose migalastat hydrochloride (GR181413A/AT1001) in healthy male Japanese subjects

来源期刊

相似文章 0

我的账户